The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•8 May 2026•

1 min read

Merck Reports $17.8 Billion Revenue and Reaffirms Guidance on Strong Oncology Sales

Key Facts

1Merck & Co. reported quarterly revenue of approximately $17.8 billion, driven by strong oncology and vaccine sales.

2The company reaffirmed its full-year guidance, highlighting the strong performance of its drug Keytruda.

Merck & Co. reported robust quarterly financial results, with total revenue reaching approximately $17.8 billion. This performance was primarily driven by strong growth in the oncology and vaccine segments, reflecting the resilience of the company's diversified portfolio. The pharmaceutical giant reaffirmed its full-year financial guidance, highlighting the exceptional performance of its flagship cancer drug, Keytruda. Furthermore, the company continues to strengthen its market position through ongoing investments in Research and Development (R&D) to expand its product pipeline. Analysts suggest that such consistent earnings growth bolsters investor confidence within the healthcare sector. These results underscore Merck's ability to maintain healthy profit margins despite broader global economic challenges.